Company intelligence / Profile preview

ITM Isotope Technologies Munich

Garching, Bavaria, Germanyitm-radiopharma.com ↗

Ownership: Private
Employees: ~501
Development stage: Phase 3

Overview

Developing radiopharmaceuticals with two Phase III programs, including ITM-11 for GEP-NETs. Operates as global supplier of Lutetium-177 and Actinium-225.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalsTargeted radionuclide therapyTheranostics
Industry: Biotech

Drug pipeline

23 assets

lutetium Lu 177-edotreotide

22 more assets in the full pipeline.

Request access →

Partnerships

Alpha-9 Oncology - Ac-225 supply agreement[9]Canadian Nuclear Laboratories - Actineer JV[9]Multiple pharmaceutical partners mentioned in pipeline collaborations[5][10]

Beyond the preview

Go deeper on ITM Isotope Technologies Munich.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITM Isotope Technologies Munich.

Explore the full profile